Johnson & Johnson appoints Dr. John Reed as EVP, Pharmaceuticals, R&D

Lupin receives approval from USFDA for Glycopyrrolate Injection USP

The approval for Glycopyrrolate clears the path for more internally manufactured injectable products

Lupin Q2 FY23 revenue up 3.9%; Profit down 71%

With the recent sales force expansion and new product launches, we expect to be back to above-market growth

Budget 2023-24: Industry welcomes focus on medical research and pharma innovation

It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047

Lupin receives tentative approval from USFDA for DETAF tablets

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries

Innova Captab gets SEBI nod to raise funds via IPO

The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)

Moderna to acquire Oriciro Genomics

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”

IIT Kanpur and Apollo Hospitals join hands for research collaboration

The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology